Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
The Oncologist
|
January 9, 2026
How Often Do Oncologists Receive Industry Payments from Competing Companies?
Helen M Keetley, Ziad Zakaria, Grace Gallagher, et al.
Journal of the National Cancer Institute
|
March 30, 2026
Use of Low-Value Cancer Care in Practices Acquired by Private Equity Firms
Aaron P Mitchell, Miranda B Lam, Caroline Carlin, et al.
JCO Oncology Practice
|
December 11, 2025
Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast Cancer
Yashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, et al.
Journal of the National Cancer Institute
|
May 20, 2026
Response to Yu, Wang, and Ge
Yashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, et al.
Journal of the National Cancer Institute
|
March 5, 2026
Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer
Yashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
The Oncologist
|
January 9, 2026
How Often Do Oncologists Receive Industry Payments from Competing Companies?
Helen M Keetley, Ziad Zakaria, Grace Gallagher, et al.
Journal of the National Cancer Institute
|
March 30, 2026
Use of Low-Value Cancer Care in Practices Acquired by Private Equity Firms
Aaron P Mitchell, Miranda B Lam, Caroline Carlin, et al.
JCO Oncology Practice
|
December 11, 2025
Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast Cancer
Yashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, et al.
Journal of the National Cancer Institute
|
May 20, 2026
Response to Yu, Wang, and Ge
Yashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, et al.
Journal of the National Cancer Institute
|
March 5, 2026
Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer
Yashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, et al.
Page
of 1